Skip to main content

Advertisement

SpringerLink
Log in

Correlation of HER2 gene status assessment by fluorescence in situ hybridization between histological sections and cytological specimens of breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

While HER2 gene detection in cytological specimens using fluorescence in situ hybridization (FISH) has been reported, the appropriate criteria for such specimens remain controversial.

Methods

Fine needle aspiration (FNA) samples collected from surgically resected breast cancer specimens were rinsed in a cytopreservative solution containing fixative. Then, slides of the FNA samples were prepared by liquid-based cytology (LBC) (ThinPrep system, Hologic) according to the manufacturer’s instructions, and a PathVision HER2 DNA probe kit (Abbott) was used for FISH staining. The results were evaluated using an automated MetaCyte imaging system (MetaSystems, Altlussheim, Germany). HER2 gene amplification was scored using the HER2/chromosome enumeration probe 17 (CEP17) signal count ratio as follows: amplified, >2.2; equivocal, 1.8–2.2; and unamplified, <1.8. The cytology results were compared with the histology results from concordant cases.

Results

Successful results were obtained in 98 of 100 cases, and results from the FNA specimens were in agreement with those from the histological sections in 97 of these 98 cases (accuracy rate, 99 %; kappa, 0.962).

Conclusions

FISH-based assessment of the HER2 gene status is consistent between histological sections and cytological specimens of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, Barbieri E, Dieci MV. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases. Impact on patient management. Oncologist. 2008;13:838–44.

    Article  CAS  PubMed  Google Scholar 

  2. Idirisinghe PK, Thike AA, Cheok PY, Tse GM, Lui PC, Fook-Chong S, Wong NS, Tan PH. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol. 2010;133:416–29.

    Article  PubMed  Google Scholar 

  3. Kumaki N, Umemura S, Tang X, Saito Y, Suzuki Y, Tokuda Y. Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2, and Ki-67. Breast Cancer. 2011;18:98–102.

    Article  PubMed  Google Scholar 

  4. Leung SW, Bédard YC. Estorogen and progesterone receptor contents in ThinPrep-processed fine-needle aspirates of breast. Am J Clin Pathol. 1999;112:50–6.

    CAS  PubMed  Google Scholar 

  5. Nishimura R, Aogi K, Yamamoto T, Takabatake D, Takabatake S, Teramoto N, Kagawa A, Morita S. Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch. 2011;458:153–8.

    Article  CAS  PubMed  Google Scholar 

  6. Konofaos P, Kontzoglou K, Georgoulakis J, Megalopoulou T, Zoumpouli C, Christoni Z, Papadopoulos O, Kouraklis G. The role of ThinPrep cytology in the evaluation of estrogen and progesterone receptor content of breast tumors. Surg Oncol. 2006;15:257–66.

    Article  CAS  PubMed  Google Scholar 

  7. Mezzelani A, Alasio L, Bartoli C, Bonora M, Pierotti M, Rilke F, Pilotti S. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer. 1999;80:519–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bofin AM, Ytterhus B, Martin C, O’Leary JJ, Hagmar BM. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol. 2004;122:110–9.

    Article  CAS  PubMed  Google Scholar 

  9. Beatty BG, Bryant R, Wang W, Ashikaga T, Gibson PC, Leiman G, Weaver DL. HER-2/neu detection in fine-needle aspirates of breast cancer. Am J Clin Pathol. 2004;122:246–55.

    Article  CAS  PubMed  Google Scholar 

  10. Nizzoli R, Bozzetti C, Crafa P, Naldi N, Guazzi A, DiBlasio B, Camisa R, Cascinu S. Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagn Cytopathol. 2003;28:142–6.

    Article  PubMed  Google Scholar 

  11. Gu M, Ghafari S, Zhao M. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. Acta Cytol. 2005;49:471–6.

    Article  PubMed  Google Scholar 

  12. Itoh H, Miyajima Y, Umemura S, Osamura RY. Lower HER-2/Chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers. Three-dimensional analysis of intranuclear localization of centromere 17 and HER-2 signals. Cancer Cytopathol. 2008;114:134–40.

    Article  Google Scholar 

  13. Moriki T, Takahashi T, Ueta S, Mitani M, Ichien M. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma. Correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol. 2004;30:251–6.

    Article  PubMed  Google Scholar 

  14. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.

    CAS  PubMed  Google Scholar 

  15. McManus DT, Patterson AH, Maxwell P, Humphreys MW, Aderson NH. Fluorescence in situ hybridization detection of erbB2 amplification in breast cancer fine needle aspirates. Mol Pathol. 1999;52:75–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2000;13:37–45.

    Article  CAS  PubMed  Google Scholar 

  17. Bozzetti C, Nissoli R, Guazzi A, Flora M, Bassano C, Crafa P, Naldi N, Cascinu S. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol. 2002;13:1398–403.

    Article  CAS  PubMed  Google Scholar 

  18. Wolff AC, Hammond MEH, Hicks D, Dowsett M, McShane L, Allison K, Allred D, Bartlett J, Bilous M, Fitzgibbons P, Hanna W, Jenkins R, Mangu P, Paik S, Perez E, Press M, Spears P, Vance G, Viale G, Hayes D. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported, in part, by the National Hospital Organization Clinical Research Fund and the National Cancer Center Research and Development Fund.

Conflict of interest

The authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime, 791-0280, Japan

    Rieko Nishimura, Akihiro Kagawa, Sachiko Tamogami, Kenta Kojima & Masakazu Satou

  2. Division of Clinical Biostatistics, Section of Cancer Prevention and Epidemiology, Clinical Research Center, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

    Natsumi Yamashita & Norihiro Teramoto

  3. Department of Pathology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

    Norihiro Teramoto

  4. Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

    Kenjiro Aogi

Authors
  1. Rieko Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akihiro Kagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sachiko Tamogami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenta Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masakazu Satou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Natsumi Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Norihiro Teramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenjiro Aogi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rieko Nishimura.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nishimura, R., Kagawa, A., Tamogami, S. et al. Correlation of HER2 gene status assessment by fluorescence in situ hybridization between histological sections and cytological specimens of breast cancer. Breast Cancer 23, 211–215 (2016). https://doi.org/10.1007/s12282-014-0552-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-014-0552-0

Keywords

Search

Navigation